What were the patient characteristics, eculizumab (Soliris) treatment regimen, and outcomes in the Duke study of atypical hemolytic uremic syndrome (aHUS)?

Duke Study on Atypical Hemolytic Uremic Syndrome (aHUS)

I cannot identify a specific "Duke study" on aHUS with eculizumab (Soliris) in the provided evidence. The evidence includes Italian consensus guidelines, FDA labeling, and various research studies from other institutions, but no study explicitly labeled as originating from Duke University.

What the Available Evidence Shows About aHUS Treatment with Eculizumab

Patient Characteristics in aHUS Studies

The most relevant multi-patient study 1 included 9 patients treated with eculizumab for aHUS and revealed:

• Most patients were Black (n=5), highlighting the lack of diversity in aHUS research
• Most had Medicare or Medicaid insurance (n=5) rather than private insurance
• Genetic mutations were tested in only 5 of 9 patients, with results not fully detailed
• The study emphasized this represents the first case series where most patients are Black, exposing a significant research gap

Standard Eculizumab Treatment Regimen for aHUS

According to FDA labeling 2, the approved dosing for adults (≥18 years) with aHUS is:

• Induction phase: 900 mg weekly for 4 weeks
• Fifth dose: 1200 mg at week 5 (one week after fourth dose)
• Maintenance: 1200 mg every 2 weeks thereafter

Critical pre-treatment requirements 2:

• Meningococcal vaccination (serogroups A, C, W, Y, and B) at least 2 weeks before first dose
• If urgent therapy needed, provide antibiotic prophylaxis with penicillin (or macrolides if penicillin-allergic) during treatment

Treatment Outcomes from Available Studies

The most compelling outcome data comes from a 2017 study 3 showing timing matters critically:

• Patients treated within ≤7 days of aHUS manifestation had mean eGFR improvement of 57 ml/min/1.73 m² at 1 year
• Patients treated >7 days had only 23 ml/min/1.73 m² improvement (p=0.0098)
• 17/21 patients (81%) in the early treatment group achieved sustained eGFR increase (≥15 ml/min/1.73 m²) versus 36/76 (47%) in delayed treatment group
• Multivariate analysis identified independent predictors of better eGFR recovery: shorter time to treatment, younger age, higher baseline LDH, and lower baseline hemoglobin

Long-term outcomes from the largest observational study 4 with 93 patients:

• 55% remained on continuous eculizumab therapy
• 45% discontinued, but 50% of those who stopped required reinitiation
• Mean eGFR improved rapidly and remained stable for up to 6 years on treatment
• Patients who discontinued showed declining renal function over time
• Higher off-treatment TMA rates occurred in: patients <18 years at diagnosis, those with genetic/autoimmune complement abnormalities, or history of multiple prior TMAs

The 2018 dialysis-dependent cohort study 5 comparing eculizumab to plasma exchange:

• 80% of eculizumab-treated patients achieved complete kidney function recovery versus 38.5% with plasma exchange alone
• 100% stopped dialysis versus 50% with plasma exchange alone
• No relapses occurred in eculizumab group versus 11.5% with plasma exchange alone

Safety Profile

Across studies, eculizumab demonstrated favorable safety 4, 6:

• Three definite and one possible meningococcal infections (all resolved with treatment)
• Occasional elevated liver enzymes (fully recovered)
• One case of severe thrombocytopenia 1
• Three deaths unrelated to eculizumab 4

Treatment Discontinuation Considerations

Current evidence 7 emphasizes that discontinuation carries risk:

• Eculizumab discontinuation can lead to aHUS recurrence and renal failure
• Thorough risk factor assessment is essential before discontinuation, including:
  • Genetic testing results (patients without pathogenic variants may be candidates)
  • Age at disease onset (pediatric onset = higher relapse risk)
  • History of multiple TMA episodes (higher relapse risk)
  • Duration of disease stability

One recent case report 8 successfully discontinued eculizumab after 12 months in a patient without genetic abnormalities, with no recurrence for 3 years, supporting selective discontinuation in low-risk patients.

Critical Treatment Timing

Italian consensus guidelines 7 achieved consensus that initiating appropriate treatment within 4-8 hours from diagnosis is essential, as delays are associated with increased morbidity and mortality. This aligns with the research showing dramatically better outcomes with treatment initiation ≤7 days 3.

Common Pitfalls to Avoid

• Do not delay treatment waiting for genetic testing results - approximately 40-50% of aHUS patients have no identifiable mutation 7
• Do not assume all three clinical signs (hemolytic anemia, thrombocytopenia, renal involvement) will be present at onset - nearly 50% of cases lack all three initially 7
• Do not discontinue eculizumab without comprehensive risk stratification including genetic testing, age at onset, and TMA history 4
• Do not forget meningococcal prophylaxis - this is a black box warning with potentially fatal consequences 2